Meng Max
Urol Oncol. 2017 May;35(5):311-312. doi: 10.1016/j.urolonc.2017.03.004. Epub 2017 Mar 27.
With the incidence of renal cell carcinoma on the rise treatment options for the small renal mass have broadened. Cryoablation is increasingly used as a therapeutic option for renal tumors in select cases. However, studies with long-term oncologic outcomes are sparse. We evaluated the long-term oncologic outcomes of laparoscopic renal mass cryoablation.
We reviewed our laparoscopic cryoablation database for patients treated with laparoscopic cryoablation from October 1997 to February 2005. Patients with less than 3 months of followup were excluded from study. Patient and tumor characteristics, and perioperative outcomes, including complications, were recorded. Recurrence-free, cancer specific and overall survival was analyzed using Kaplan-Meier curves.
A total of 142 tumors in 138 consecutive patients were treated with laparoscopic cryoablation. Mean age of the cohort was 66.35 years. Of the patients 99 (71.7%) were male and 39 (28.3%) were female. Mean body mass index was 29.15kg/m(2) and median ASA score was 3. A solitary kidney was present in 23 patients (16.2%). Mean tumor size on cross-sectional imaging was 2.4cm. The mean preoperative and postoperative estimated glomerular filtration rate was 66.72 and 61.00ml per minute, respectively. The postoperative estimated glomerular filtration rate was determined at a mean±SD of 15.17±10.99 months of followup. The median R.E.N.A.L. nephrometry score was 5. Of the 142 tumors 100 were diagnosed as renal cell carcinoma after histopathological examination of the biopsy specimen. At 3, 5, and 10 years in patients diagnosed with renal cell carcinoma estimated recurrence-free survival was 91.4%, 86.5%, and 86.5%, estimated cancer specific survival was 96.8%, 96.8%, and 92.6%, and estimated overall survival was 88.7%, 79.1%, and 53.8%, respectively. Mean followup was 98.8±54.2 months in those diagnosed with renal cell carcinoma. Mean time to recurrence was 2.3 years. The latest experienced recurrence was 4.4 years after laparoscopic cryoablation. There was a postoperative complication rate of 10.6% with a total of 15 complications.
Laparoscopic cryoablation achieves good long-term oncologic outcomes for localized small renal masses. It can safely be used in patients who cannot undergo or are unwilling to accept the risks of partial nephrectomy. Mean time to recurrence was 2.3 years and all recurrences developed within 4.4 years of initial treatment.
随着肾细胞癌发病率的上升,小肾肿块的治疗选择有所增加。冷冻消融在特定病例中越来越多地被用作肾肿瘤的治疗选择。然而,关于长期肿瘤学结局的研究较少。我们评估了腹腔镜肾肿块冷冻消融的长期肿瘤学结局。
我们回顾了1997年10月至2005年2月接受腹腔镜冷冻消融治疗的患者的腹腔镜冷冻消融数据库。随访时间少于3个月的患者被排除在研究之外。记录患者和肿瘤特征以及围手术期结局,包括并发症。使用Kaplan-Meier曲线分析无复发生存率、癌症特异性生存率和总生存率。
138例连续患者共142个肿瘤接受了腹腔镜冷冻消融治疗。队列的平均年龄为66.35岁。患者中,99例(71.7%)为男性,39例(28.3%)为女性。平均体重指数为29.15kg/m²,中位ASA评分是3。23例患者(16.2%)存在孤立肾。横断面成像上肿瘤的平均大小为2.4cm。术前和术后估计肾小球滤过率分别为每分钟66.72和61.00ml。术后估计肾小球滤过率在平均随访15.17±10.99个月时测定。R.E.N.A.L.肾计量评分的中位数为5。142个肿瘤中,100个在活检标本的组织病理学检查后被诊断为肾细胞癌。在诊断为肾细胞癌的患者中,3年、5年和10年的估计无复发生存率分别为91.4%、86.5%和86.5%,估计癌症特异性生存率分别为96.8%、96.8%和92.6%,估计总生存率分别为88.7%、79.1%和53.8%。诊断为肾细胞癌的患者平均随访时间为98.8±54.2个月。平均复发时间为2.3年。最近一次经历的复发是在腹腔镜冷冻消融后4.4年。术后并发症发生率为10.6%,共有15例并发症。
腹腔镜冷冻消融对于局限性小肾肿块可取得良好的长期肿瘤学结局。它可安全地用于不能接受或不愿接受部分肾切除术风险的患者。平均复发时间为2.3年,所有复发均在初始治疗后4.4年内发生。